Calliditas Therapeutics AB Overview

Calliditas Therapeutics AB Research & Development

Research & Development expenses for CALT.

Quarterly R&D Expenses

$120.72M

↑ 35.66% YoY

As of Jun 30, 2024

Annual R&D Expenses (TTM)

$557.91M

↑ 32.6% YoY

Trailing 12 months ending Jun 30, 2024

Average R&D Expenses (Comparison Companies)

Research & Development History

Research & Development Comparison

Annual Research & Development Growth Rate (%)

Annual Research & Development Growth (Absolute)

Jump to metric

Total Revenue Cost of Revenue Gross Profit Research & Development Selling, General & Admin Operating Income Other Income Expense Net EBIT Income Tax Net Income Profit Margin